Strong Development Pipeline

A diverse pipeline designed to address significant unmet medical needs

We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.

Brentuximab Vedotin

Hodgkin Lymphoma (HL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

CheckMate 812: Relapsed HL (+ nivolumab)

Enrolling

Frontline HL in patients ≥ 60 (+ nivolumab)

Enrolling

Second-line HL (+ nivolumab)

Enrolling

CheckMate 744: Relapsed cHL (+ nivolumab)

Enrolling

Non-Hodgkin Lymphoma (NHL)

Target: CD30

Technology Platform: ADC using MMAE

Collaborator:

CheckMate 436: Relapsed NHL (+ nivolumab)

Enrolling

Late-Stage Programs

Target: Nectin-4

Technology Platform: ADC using MMAE

Collaborator:

EV-301: Urothelial cancer post PD(L)-1 inhibitor


EV-201: Urothelial cancer post PD(L)-1 inhibitor

Topline results of cohort 1 announced / Pivotal / Enrolling

EV-103: First-line urothelial cancer (+ pembrolizumab and/or chemotherapy)

Enrolling

Target: Tissue factor

Technology Platform: ADC using MMAE

Collaborator:

innovaTV 204: Recurrent cervical cancer

Pivotal

innovaTV 205: Recurrent cervical cancer

Enrolling

innovaTV 207: Other solid tumors

Enrolling

innovaTV 208: Ovarian cancer

Enrolling

Target: HER2

HER2CLIMB: HER2-positive breast cancer

Pivotal

I-SPY 2: Neoadjuvant breast cancer

Enrolling

Early-Stage Programs

Target: LIV-1

Technology Platform: ADC using MMAE

I-SPY 2: HER2-negative breast cancer

Enrolling

Triple negative breast cancer (TNBC) (+ pembrolizumab)

Enrolling

MORPHEUS: TNBC (+ atezolizumab)

Enrolling

Breast cancer

Enrolling

SEA-BCMA

Target: BCMA

Technology Platform: Sugar engineered Antibody (SEA) technology designed to enhance antibody effector function

Multiple myeloma

Enrolling

ACTR-BCMA

Technology Platform: Novel antibody-coupled T-cell receptor (ACTR) therapy

Collaborator:

Multiple myeloma

Enrolling

Target: CD48

Technology Platform: ADC using MMAE

Relapsed/refractory multiple myeloma

Enrolling